Barrow, Hanley, Mewhinney & Strauss’s Usana Health Sciences USNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.53K Hold
212
﹤0.01% 302
2026
Q1
$3.7K Hold
212
﹤0.01% 290
2025
Q4
$4.16K Hold
212
﹤0.01% 281
2025
Q3
$5.84K Hold
212
﹤0.01% 257
2025
Q2
$6.47K Buy
212
+192
+960% +$5.45K ﹤0.01% 242
2025
Q1
$539 Sell
20
-217
-92% -$6.87K ﹤0.01% 313
2024
Q4
$8.51K Hold
237
﹤0.01% 239
2024
Q3
$8.99K Buy
237
+71
+43% +$2.92K ﹤0.01% 232
2024
Q2
$7.51K Hold
166
﹤0.01% 223
2024
Q1
$8.05K Hold
166
﹤0.01% 214
2023
Q4
$8.9K Sell
166
-18
-10% -$910 ﹤0.01% 203
2023
Q3
$10.8K Hold
184
﹤0.01% 181
2023
Q2
$11.6K Sell
184
-26
-12% -$1.66K ﹤0.01% 157
2023
Q1
$13.2K Buy
+210
New +$12.5K ﹤0.01% 145
2015
Q2
Sell
-23,632
Closed -$1.31M 340
2015
Q1
$1.31M Buy
+23,632
New +$1.21M ﹤0.01% 285

Other funds holding USNA

Barrow, Hanley, Mewhinney & Strauss's USNA Position: Q2 2026 in Review

Barrow, Hanley, Mewhinney & Strauss held its Usana Health Sciences (USNA) position steady in Q2 2026 at 212 shares worth $4.53K. The position accounts for ﹤0.01% of the portfolio, ranked #302.

Barrow, Hanley, Mewhinney & Strauss first reported a position in USNA in Q1 2015 and has held it in 15 quarters since. The position peaked at $1.31M in Q1 2015. 138 funds tracked by Wall St. Rank hold USNA as of Q2 2026.

  • Barrow, Hanley, Mewhinney & Strauss held 212 shares of Usana Health Sciences worth $4.53K as of Q2 2026.
  • Barrow, Hanley, Mewhinney & Strauss left its Usana Health Sciences share count unchanged in Q2 2026.
  • Usana Health Sciences made up ﹤0.01% of Barrow, Hanley, Mewhinney & Strauss's portfolio in Q2 2026, its #302 holding.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in Usana Health Sciences in Q1 2015 and has held it in 15 quarters since.
  • Barrow, Hanley, Mewhinney & Strauss's Usana Health Sciences position peaked at $1.31M in Q1 2015.
  • 138 funds tracked by Wall St. Rank held Usana Health Sciences as of Q2 2026.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q2 2026, filed 12 Aug 2026.